Clinical Trials
12
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
- Conditions
- Prostate CancerProstate Cancer Patients With Detectable PSA Following ProstatectomyProstate Cancer RecurrentProstate Cancer Patients Who Have Brachytherapy Seed ImplantProstate Cancer Patients Treated by RadiotherapyCryotherapy
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 220
- Registration Number
- NCT06970847
- Locations
- 🇺🇸
Biogenix Molecular, Miami, Florida, United States
🇺🇸The Urology Place, San Antonio, Texas, United States
🇺🇸XCancer, Omaha, Nebraska, United States
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 383
- Registration Number
- NCT06056830
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸Mount Sinai Doctors Urology Faculty Practice, New York, New York, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
- Conditions
- Castration-ResistantProstatic Neoplasms
- Interventions
- Drug: 64Cu-SAR-BBN
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 38
- Registration Number
- NCT05633160
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Biogenix Molecular, Miami, Florida, United States
🇺🇸BAMF Health, Inc, Grand Rapids, Michigan, United States
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
- Conditions
- Biochemical Recurrence of Malignant Neoplasm of Prostate
- Interventions
- Drug: 64Cu-SAR-BBN
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 53
- Registration Number
- NCT05407311
- Locations
- 🇺🇸
Tower Urology, Los Angeles, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Biogenix Molecular, Miami, Florida, United States
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
- Conditions
- Biochemical Recurrence of Malignant Neoplasm of Prostate
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT05249127
- Locations
- 🇺🇸
Tower Urology, Los Angeles, California, United States
🇺🇸GU Research Network, Omaha, Nebraska, United States
🇺🇸New Mexico Cancer Center, Albuquerque, New Mexico, United States
- Prev
- 1
- 2
- 3
- Next